MREO · CIK 0001719714 · FY2025 live · 2025-12-31
Mereo BioPharma Group plc
View as
Model
Classic Z
FY2025
−12.17
Zone
Distress
Prior
—
Market DD
—
1y PD
—
−12.17
Z″ −27.03
Score −12.17 · distress below 1.80, grey to 2.99, safe at 3.00 and above.
Classic Z factor contributions
X1 Working capital / assets
Short-term liquidity versus the size of the balance sheet.
0.891.2 × = 1.06X2 Retained earnings / assets
Cushion from years of profits. Share buybacks can push this negative at otherwise healthy firms.
−10.911.4 × = −15.28X3 EBIT / assets
Operating return on assets. Highest weight in the original model.
−0.873.3 × = −2.88X4 Book equity / liabilities
Book equity versus the liability stack. Mega-caps often look greyer here than they would if X4 used market cap.
8.180.6 × = 4.91X5 Sales / assets
Asset turnover — how much revenue the asset base supports.
0.011 × = 0.01
Five-year path
Need two annual 10-Ks to draw a path. The desk will pull this issuer’s filings rather than invent a series.
Overview
rule-v1
Mereo BioPharma Group plc is on classic Z at −12.17 (distress) for FY2025, from an SEC 10-K. Retained earnings / assets is the line that sets the print. This is the first live year on the desk. No market tape loaded. Classic Z was fit on manufacturers; buybacks can send retained earnings negative at otherwise healthy issuers, and X4 is book equity, not market cap.
Book screen Distress; market PD —. Tape not priced — not a single default call.
Market DD · naive Merton
No market tape yet.
Pull a year of closes (Yahoo, Nasdaq if Yahoo is limited) and size equity from Nasdaq cap or EDGAR shares. Distance-to-default and 1-year PD stay blank until then.
Sector peers
Closest Classic Z scores · 13th percentile in Healthcare.
- MODDDistressModular Medical, Inc.−12.19
- RCELDistressAVITA Medical, Inc.−12.07
- ATNMDistressActinium Pharmaceuticals, Inc.−12.32
- BOLTDistressBolt Biotherapeutics, Inc.−12.34
- PDSBDistressPDS Biotechnology Corp−12.36
- CUEDistressCue Biopharma, Inc.−11.97
- HOWLDistressWerewolf Therapeutics, Inc.−11.75
- ALGSDistressAligos Therapeutics, Inc.−11.66
KPI widgets
Current assets
$45M
Total assets
$46M
Current liabilities
$4M
Total liabilities
$5M
Working capital
$41M
Retained earnings
−$501M
EBIT
−$40M
Total sales
$500K
Book equity
$41M
Accession 0001193125-26-115226. Live rank is the latest 10-K on EDGAR (FY2025, period 2025-12-31). Classic Z is the live score. View as does not rewrite the live rank. X4 is book equity. Pulled 12 Sept 2026.